AIM ImmunoTech Amends Equity Distribution Agreement to Remove $3 Million ATM Offering Limit

On April 10, 2026, AIM ImmunoTech Inc. entered into Amendment No. 1 to its existing Equity Distribution Agreement with Maxim Group LLC, originally dated April 1, 2025. This amendment modifies the terms of the company's at-the-market (ATM) public offering. Specifically, the amendment removes the previous $3,000,000 cap on the aggregate offering price of common stock that could be sold through Maxim Group. Under the revised agreement, the company may now issue and sell shares up to the maximum amount allowed under its effective shelf registration statement on Form S-3 (File No. 333-286319), subject to authorized share limits and Form S-3 eligibility requirements. Simultaneously with the filing, the company submitted a prospectus supplement to reflect the increased number of shares available for sale. The proceeds from any future sales under this ATM facility are intended for general corporate purposes. Maxim Group continues to serve as the exclusive sales agent for the offering.